Take 5 minutes to catch up on NeurologyLive's highlights from the week ending March 5, 2021.
Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
In this NeurologyLive Cure Connections series, Philippa Cheetham, MBChB, MRCS, MD, FRCS; Jessica Ailani, MD, FAHS; and Jill Dehlin, RN, discuss the factors that differentiate migraine attacks from headaches and the impact of migraine attacks on patients’ lives.
The director of research analytics at Cure SMA discussed her recent research conducted in tandem with Novartis Gene Therapies on the economic burden and costs patients with spinal muscular atrophy and their caregivers face.
The clinical research coordinator at Massachusetts General Hospital discussed his presentation from ACTRIMS Forum 2021 on electronic pill bottle monitoring to promote MS medication adherence.
Recently announced positive data from part 1 of the FIREFISH study (NCT02913482) evaluating risdiplam (Evrysdi; PTC Therapeutics) in SMA type 1—just one of many such ongoing studies—were announced by PTC Therapeutics.
The chair of the Department of Neurology and the director of the Neuroscience Research Institute at The Ohio State University discussed his keynote lecture at ACTRIMS Forum 2021.